CAJ | 학술논문

目的：研究脂必泰联合阿托伐他汀对2型糖尿病患者血脂代谢紊乱的影响。方法选取2012年6月~2013年6月在我院进行治疗的120例2型糖尿病血脂代谢紊乱患者作为研究对象，按照治疗方法的不同分为研究组和对照组，每组60例。研究组患者采用脂必泰联用阿托伐他汀进行治疗，对照组单纯采用阿托伐他汀进行治疗。两组患者连续用药14周后，观察其治疗效果和发生不良反应情况。结果治疗前，两组血脂各项指标相比较，差异无统计学意义(P>0.05)；治疗后，两组的总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白胆固醇(LDL-C)均显著低于治疗前，高密度脂蛋白胆固醇(HDL-C)显著高于治疗前，前后差异有统计学意义(P<0.05)；治疗后，研究组的TC、TGL和LDL-C低于对照组，HDL-C高于对照组，两组差异有统计学意义(P<0.05)。治疗前，两组血糖(包括空腹血糖和餐后2 h血糖)差异无统计学意义(P>0.05)；治疗后，两组血糖均显著降低，且研究组低于对照组，差异有统计学意义(P<0.05)。治疗后，两组的丙氨酸氨基转移酶(ALT)、血尿素氮(BUN)、血清肌酐(Scr)和肌酸激酶(CK)等指标与治疗前比较均显著改善，前后差异有统计学意义(P<0.05)，但两组间的ALT、BUN、Scr和CK等各项指标相比较，差异无统计学意义(P>0.05)。两组的不良反应发生率差异无统计学意义(P>0.05)。结论脂必泰联合阿托伐他汀可以显著改善2型糖尿病血脂代谢紊乱患者的血脂和血糖，不良反应低，安全可靠，值得临床推广应用。
목적：연구지필태연합아탁벌타정대2형당뇨병환자혈지대사문란적영향。방법선취2012년6월~2013년6월재아원진행치료적120례2형당뇨병혈지대사문란환자작위연구대상，안조치료방법적불동분위연구조화대조조，매조60례。연구조환자채용지필태련용아탁벌타정진행치료，대조조단순채용아탁벌타정진행치료。량조환자련속용약14주후，관찰기치료효과화발생불량반응정황。결과치료전，량조혈지각항지표상비교，차이무통계학의의(P>0.05)；치료후，량조적총담고순(TC)、삼선감유(TG)화저밀도지단백담고순(LDL-C)균현저저우치료전，고밀도지단백담고순(HDL-C)현저고우치료전，전후차이유통계학의의(P<0.05)；치료후，연구조적TC、TGL화LDL-C저우대조조，HDL-C고우대조조，량조차이유통계학의의(P<0.05)。치료전，량조혈당(포괄공복혈당화찬후2 h혈당)차이무통계학의의(P>0.05)；치료후，량조혈당균현저강저，차연구조저우대조조，차이유통계학의의(P<0.05)。치료후，량조적병안산안기전이매(ALT)、혈뇨소담(BUN)、혈청기항(Scr)화기산격매(CK)등지표여치료전비교균현저개선，전후차이유통계학의의(P<0.05)，단량조간적ALT、BUN、Scr화CK등각항지표상비교，차이무통계학의의(P>0.05)。량조적불량반응발생솔차이무통계학의의(P>0.05)。결론지필태연합아탁벌타정가이현저개선2형당뇨병혈지대사문란환자적혈지화혈당，불량반응저，안전가고，치득림상추엄응용。
Objective To study the influence of Zhibitai combined with atorvastatin in treatment of lipid metabolism disorder in patients with type 2 diabetes. Methods 120 patients with type 2 diabetes and lipid metabolism disorder treated into our hospital from June 2012 to June 2013 were selected as research object.They were divided into the study group and the control group based on the treatment regimen. The study group was treated with Zhibitai and ator-vastatin,while control group was treated with atorvastatin.The treatment effect and adverse reactions in two groups was observed after continuous 14 weeks administration. Results Before treatment,the indicators of blood lipids in two groups were compared,the differences were not significant (P>0.05).After treatment,total cholesterol(TC),three acyl glycerin(TG) and low-density lipoprotein cholesterol (LDL-C) in two groups were significantly lower than those of before treatment, high density lipoprotein cholesterol (HDL-C) was significantly higher than that of before treatment,the differences were statistically significant before and after treatment (P<0.05).TC,TG and LDL-C in study group were lowen than those of control group, HDL-C in study group was higher than that of control group, the differences were significant between two groups (P<0.05).Before treatment,there has no significant difference of blood glucose (fasting and 2 h postprandial plasma glucose) in two groups (P>0.05).After treatment,the blood sugar in two groups was significantly decreased,and study group was lower than the control group,the difference was significant (P<0.05).After treatment,ALT,BUN,Scr and CK in two groups were all improved compared with before treatment,the differences were significant before and after treatment (P<0.05),but there was no statistical significance of ALT,BUN,Scr,CK between two groups (P>0.05).There was no statistical significance of adverse reaction incidence between two groups (P>0.05). Conclusion Zhibitai combined with atorvastatin can significantly improve the blood lipid and glucose status of patients with type 2 diabetes and lipid metabolism disorder.It is safe with low adverse reaction incidence,and is worthy of clinic application.